Houston-based GoCo.io has acquired a company that aims to improve the work-from-home employee experience. Courtesy of GoCo

A Houston software startup has made a strategic acquisition to account for the increasingly large number of companies employing a remote-first workforce.

After closing a $15 million series B funding round last year, GoCo.io, an HR solutions software platform, has acquired WFHomie, a platform that helps remote-first companies enhance the employee experience as well as keep up with people analytics. According to GoCo research, most HR professionals report that they are being asked to retain top talent — employee engagement programs are key to driving that retention, the company says in a news release.

“We know that employee experience is top of mind for SMBs and the HR teams that support them,” says Nir Leibovich, co-founder and CEO of GoCo, in the release. “Our team and our platform are growing rapidly in support of our mission to empower HR professionals, and this acquisition is a key step in that direction.

"It’s clear that the leadership of WFHomie share our vision, passion, and excitement for creating innovative products that help companies build better workplaces," he continues. "We’re confident that the WFHomie team will bring the expertise and agility we need to ship new products and expand our service offerings in line with that vision.”

The details of the transaction were not disclosed. The WFHomie team will be on boarded at GoCo.

Founded in November of 2020 in direct response to the pandemic, Toronto-based WFHomie raised $1.6 million in seed funding in 2021.

“Nir and the leadership team at GoCo are dedicated to building a future where HR and People Ops leaders have the bandwidth to support their employees effectively and create thriving, high-performing workplaces” says Pavla Bobosikova, co-founder and CEO of WFHomie in the news release. “We share the same vision – to improve work-life for employees, while empowering organizations to operate more effectively.”

Founded in 2015 by Leibovich, Jason Wang, and Michael Gugel, GoCo has raised $27.5 million to date and has over 100 employees, according to LinkedIn.

Following a $7 million raise, Houston-based GoCo is looking to grow. Courtesy of GoCo

Houston B-to-B tech startup gears up for growth following $7 million Series A

Serious series

A Houston startup looking to digitize the human resources industry just completed a reassuring round of funding. GoCo closed its Series A funding round led by ATX Seed Ventures alongside UpCurve, Inc. at $7 million.

GoCo, which was founded by CEO Nir Leibovich, Chief Technology Officer Jason Wang, and Chief Product Officer Michael Gugel, is out to bring the much-maligned HR tasks into the digital world. The funding round brings GoCo's total funding to $12.5 million. Leibovich said the new capital will be allocated to hiring across all departments, further platform development to extend the breadth of offerings and to broadly expand the company's customer base.

"Today, we have 6,200 customers across the U.S. and around the world," Leibovich tells InnovationMap. "And we have 25 employees. We're looking to double and triple — if not quadruple — that across 2019."

The company has a solid partnership network with employee benefit insurance agencies like OneDigital and PayneWest, and general agencies like Word & Brown, to offer GoCo's technology as an enhancement to their existing insurance benefits services clients. GoCo also auto-syncs with leading payroll providers ADP, PayChex, Paylocity, Intuit Quickbooks and more, thus uniquely enabling businesses to maintain their benefits broker and payroll provider by integrating with GoCo's platform.

"This Series A and the potential addition of UpCurve's distribution channel to reach hundreds-of-thousands of new customers continues our mission to free SMBs and HR professionals from outdated and tedious administrative burdens. When these professionals look at current HR and benefits solutions on the market and think 'there must be a better way,' we are the better way," says Leibovich. "We want to be synonymous with modern and streamlined HR."

GoCo is backed by additional investments from Salesforce Ventures, Corp Strategics, GIS Strategic Ventures, the venture arm of Guardian Life Insurance, and Digital Insurance, the largest employee benefits-only company in the US. ATX Seed Ventures is investing for the second time.

"We are doubling down on our investment in GoCo, as it is positioned to become the platform of choice for HR professionals to break out of the chains of outdated and complex HR duties, and empowers them to spend more time on their employees and higher value tasks," says Chris Shonk, managing partner at ATX Seed Ventures, in a release. "GoCo is simply the best platform solution to do all this, and their increasing customer base supports it."

Founded in 2015, GoCo is the fusion of modern, paperless HR functions like employee onboarding, secure cloud-storage document management, eSignature workflows, time-off tracking and HR data reporting. As well, it is paired with simplified benefits enrollment and management, payroll sync and HR compliance enablement. The web and mobile based app empower employers to give employees 24/7 access to the full spectrum of a company's HR and benefits offerings.

GoCo creates platforms to onboard employees, conduct training and myriad HR tasks which, said Leibovich, free up HR personnel to handle the business of actually working with employees to grow their potential and assist companies with their missions.

"Typically, HR has lagged behind when it comes to embracing technology," says Leibovich. "Sales, marketing, development, these are places where it's become the norm to seek out tech solutions to problems. With human resources, many firms are still using that paperwork model, and often, a new hire's first day on the job – and therefore their first impression of a company — is filling out forms."

Leibovich had founded two companies before, one based in analytics that they sold to Zinga, the other a biotech firm. It was the biotech venture that brought the Austin-based trio to Houston. Looking around the landscape, Leibovich said he and his partners liked the fact that Houston was a city on the move, with a highly skilled workforce and companies keen on finding tech solutions to their challenges. The city's "if you can dream it, you can do it here" vibe kept the group here as they launched GoCo. Leibovich said he thinks that, in terms of its startup ventures, Houston is where Austin was 10 years ago. And he believes that continued successes in the tech and startup culture will breed more success in the Bayou City.

"This is an ecosystem that is coming together to attract even more talent for ventures like this," he said. "Funding is going to ramp up, and we see Houston as a place where we — and other companies — can create something really special. This is a great place to do business."

All-in-one platform

Courtesy of GoCo

GoCo is the fusion of modern, paperless HR functions like employee onboarding, secure cloud-storage document management, eSignature workflows, time-off tracking and HR data reporting.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.